Splenic iron decreases without change in volume or liver parameters during luspatercept therapy

Christopher C Denton; Sadanand Vodala; Saranya Veluswamy; Thomas C Hofstra; Thomas D Coates; John C Wood

doi:10.1182/blood.2023021839

Splenic iron decreases without change in volume or liver parameters during luspatercept therapy

Blood. 2023 Nov 30;142(22):1932-1934. doi: 10.1182/blood.2023021839.

Authors

Christopher C Denton^{1

2}, Sadanand Vodala³, Saranya Veluswamy^{1

2}, Thomas C Hofstra^{1

2}, Thomas D Coates^{1

2}, John C Wood^{2

4}

Affiliations

¹ Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.
² Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA.
³ Bristol Myers Squibb, Summit, NJ.
⁴ Division of Cardiology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA.

PMID: 37704579
DOI: 10.1182/blood.2023021839

Abstract

Splenic iron decreased whereas liver iron was stable during luspatercept therapy in some individuals with thalassemia. This suggests a reduction of ineffective erythropoiesis changes the organ distribution of iron and demonstrates that liver iron concentration alone may not accurately reflect total body iron content. This article describes data from subjects enrolled in BELIEVE (NCT02604433) and BEYOND (NCT03342404).

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Activin Receptors, Type II
Erythropoiesis
Humans
Iron*
Liver
beta-Thalassemia* / drug therapy

Substances

Activin Receptors, Type II
Iron
luspatercept

Associated data

ClinicalTrials.gov/NCT03342404
ClinicalTrials.gov/NCT02604433